About c esterase inhibitor
Human plasma-derived C1 esterase inhibitor
Used for
- Prevention of hereditary angioedema attacks in adults and children.
- Treatment of acute hereditary angioedema attacks in children; acute treatment is not an approved use in the United States.
Usual adult dose
Prevention: 1,000 IU intravenously every 3 or 4 days. U.S. labeling also allows 1,000 IU for acute attacks.
Usual dose in children
Prevention, ages 6–11: 500 IU every 3 or 4 days. Ages 2–5: 500 IU twice weekly. Acute attacks: 1,000 IU intravenously.
Common side effects
- Headache
- Nausea
- Rash
- Injection-site reactions
Important warnings
- Serious allergic reactions, including anaphylaxis, can occur.
- Blood clots have been reported, especially with risk factors or high doses.
- Plasma-derived products may carry a very small infectious-agent transmission risk.
- Acute attacks affecting the airway can be life-threatening.
Pregnancy
Human pregnancy data are limited. Use when needed; hereditary angioedema itself may worsen during pregnancy.
Breastfeeding
It is unknown whether the medicine enters breast milk. Consider the mother's need and potential infant risks.
Interactions
- No specific drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.